文献速递泌尿男性生殖肿瘤

肌层浸润性膀胱癌新辅助剂量密集吉西他滨联合顺铂的多中心前瞻性II期试验

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
PubMed 文献 · J Clin Oncol · 2018-05-09

这项多中心前瞻性II期研究评估了6周期新辅助剂量密集吉西他滨联合顺铂(ddGC)治疗肌层浸润性膀胱癌的疗效与耐受性,主要终点为病理降期至非肌层浸润性疾病(<pT2N0)。46例可评估患者中57%达到主要终点,病理缓解与无复发生存和总生存改善相关;携带推测有害DNA损伤反应(DDR)基因改变者化疗敏感性更高。

要点

  • 6周期ddGC新辅助方案可使57%可评估患者降期至<pT2N0,且未因毒性导致患者未能接受根治性膀胱切除术。
  • 推测有害DDR基因改变对<pT2N0的阳性预测值为89%,携带者在2年中位随访时无复发。

核心结论

  • 6周期ddGC是肌层浸润性膀胱癌活跃且耐受性良好的新辅助方案。
  • 治疗前肿瘤组织存在推测有害DDR基因改变,强烈预测化疗敏感性、持久缓解及更优长期生存。

研究设计与样本

  • 方案为吉西他滨2500 mg/m2第1天联合顺铂35 mg/m2第1、2天,每2周1次,共6周期,随后行根治性膀胱切除术。
  • 主要终点为病理降期至非肌层浸润性疾病(<pT2N0);未行根治性膀胱切除术者判定为无应答。
  • 治疗前肿瘤行下一代测序以识别化疗敏感性预测因子。

主要发现

  • 46例可评估患者中57%降期至<pT2N0,主要终点达到。
  • 病理缓解与无复发生存和总生存改善相关。
  • 无患者因化疗相关毒性未能接受根治性膀胱切除术。
  • 最常见治疗相关毒性为贫血(3级占12%)。

关键数值与推荐

  • 推测有害DDR基因改变对<pT2N0的阳性预测值为89%。
  • 携带有害DDR基因改变者在2年中位随访时无复发。

临床怎么用

  • ddGC可作为肌层浸润性膀胱癌新辅助治疗的可选方案,需关注贫血等毒性及剂量调整。
  • 治疗前DDR基因改变检测有助于筛选化疗敏感、可能获得持久缓解的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have yielded favorable outcomes compared with standard-dose chemotherapy, yet the optimal neoadjuvant regimen remains undefined. We assessed the efficacy and tolerability of six cycles of neoadjuvant dose-dense gemcitabine and cisplatin (ddGC) in patients with MIBC. Patients and Methods In this prospective, multicenter phase II study, patients received ddGC (gemcitabine 2,500 mg/m2 on day 1 and cisplatin 35 mg/m2 on days 1 and 2) every 2 weeks for 6 cycles followed by RC. The primary end point was pathologic downstaging to non-muscle-invasive disease (< pT2N0). Patients who did not undergo RC were deemed nonresponders. Pretreatment tumors underwent next-generation sequencing to identify predictors of chemosensitivity. Results Forty-nine patients were enrolled from three institutions. The primary end point was met, with 57% of 46 evaluable patients downstaged to < pT2N0. Pathologic response correlated with improved recurrence-free survival and overall survival. Nineteen patients (39%) required toxicity-related dose modifications. Sixty-seven percent of patients completed all six planned cycles. No patient failed to undergo RC as a result of chemotherapy-associated toxicities. The most frequent treatment-related toxicity was anemia (12%; grade 3). The presence of a presumed deleterious DNA damage response (DDR) gene alteration was associated with chemosensitivity (positive predictive value for < pT2N0 [89%]). No patient with a deleterious DDR gene alteration has experienced recurrence at a median follow-up of 2 years. Conclusion Six cycles of ddGC is an active, well-tolerated neoadjuvant regimen for the treatment of patients with MIBC. The presence of a putative deleterious DDR gene alteration in pretreatment tumor tissue strongly predicted for chemosensitivity, durable response, and superior long-term survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Iyer G, Balar AV, Milowsky MI, et al. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2018. PMID: 29742009. doi:10.1200/JCO.2017.75.0158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。